Categories
Change Password!
Reset Password!
SGLT2 inhibitors and GLP-1 receptor agonists reduce all-cause mortality and MACE in adults with T2DM, while insulin, DPP-4 inhibitors, and tirzepatide show no mortality benefit.
Newer pharmacologic treatments for type 2 diabetes mellitus (T2DM) are increasingly used worldwide as clinicians look beyond glucose control towards therapies that may influence survival, cardiovascular (CV) disease, and kidney outcomes. Drug classes such as sodium–glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and long-acting insulins now occupy a central role in diabetes management, yet their relative benefits and risks remain an area of active evaluation.
Against this backdrop, a systematic review and network meta-analysis assessed the effectiveness, comparative benefits, and harms of these therapies in adults with T2DM, focusing on mortality, CV events, and renal outcomes beyond glycemic control. The analysis was based on a large body of randomized clinical trial evidence drawn from MEDLINE and EMBASE, covering studies published between 2010 and January 2023 and focusing on adults with T2DM treated for at least 1 year.
Only trials enrolling 500 or more participants were included, ensuring the findings reflected long-term and population-level outcomes across widely used diabetes drug classes, including SGLT2 inhibitors, GLP1 agonists, DPP4 inhibitors, long-acting insulins, and relevant comparator therapies. Data accuracy was reinforced through independent verification, while bias and evidence strength were evaluated using established grading standards. Clinical relevance was addressed by applying predefined thresholds for minimally important differences developed with the American College of Physicians.
Across 130 publications representing 84 randomized trials, the analysis showed clear outcome differences between drug classes. Compared with usual care, SGLT2 inhibitors and GLP1 agonists were linked to lower all-cause mortality and fewer major adverse cardiovascular events (MACE), with evidence ranging from moderate to high certainty. SGLT2 inhibitors were also associated with slower chronic kidney disease progression and fewer hospitalizations for heart failure, while GLP1 agonists were associated with a reduced risk of stroke.
Serious adverse events and episodes of severe hypoglycemia occurred less often with SGLT2 inhibitors, although the reductions did not meet predefined thresholds for minimal clinical importance. By contrast, insulin, tirzepatide, and DPP4 inhibitors showed no reduction in all-cause mortality when measured against usual care. When directly compared with insulin, both SGLT2 inhibitors and GLP1 agonists demonstrated lower mortality, and GLP1 agonists also outperformed DPP4 inhibitors on survival outcomes.
SGLT2 inhibitors reduced MACE when compared with DPP4 inhibitors and sulfonylureas, while both SGLT2 inhibitors and GLP1 agonists consistently lowered the risk of severe hypoglycemia relative to sulfonylureas and insulin. Thus, SGLT2 inhibitors and GLP1 agonists provided consistent survival and CV benefits in adults with T2DM, along with additional kidney, heart failure, and safety advantages not seen with other therapies, highlighting clear differences between modern drug classes.
Annals of Internal Medicine
Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians
Tyler Drake et al.
Comments (0)